Pulmonx Corporation (NASDAQ:LUNG) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Pulmonx Corporation (NASDAQ:LUNG) has received a consensus rating of "Moderate Buy" from analysts, with four maintaining a hold rating and five issuing buy ratings. The average one-year price target is approximately $7.66.
• Insider activity includes Director Daniel P. Florin acquiring 23,321 shares at $3.06 each, indicating a 24.83% increase in his stake, while CEO Steven S. Williamson sold 9,923 shares at $3.13, representing a 2.64% decrease in his ownership.
• The company's latest quarterly earnings reported ($0.38) earnings per share, surpassing estimates by $0.02, with revenue of $23.86 million against expectations of $23.46 million.

Shares of Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $7.6643.

A number of equities research analysts have weighed in on the stock. Canaccord Genuity Group cut their price target on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Citigroup cut their price target on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Lake Street Capital cut their price target on shares of Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Wall Street Zen downgraded shares of Pulmonx from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd. Finally, Wells Fargo & Company cut their price target on shares of Pulmonx from $6.00 to $3.00 and set an "equal weight" rating for the company in a report on Friday, August 1st.

Pulmonx Price Performance

NASDAQ LUNG traded down $0.05 on Monday, reaching $1.71. The company's stock had a trading volume of 398,425 shares, compared to its average volume of 930,463. Pulmonx has a twelve month low of $1.47 and a twelve month high of $9.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.63 and a current ratio of 5.35. The stock has a market cap of $69.68 million, a PE ratio of -1.20 and a beta of 0.43. The firm's 50 day moving average is $2.34 and its two-hundred day moving average is $4.33.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. The company had revenue of $23.86 million during the quarter, compared to the consensus estimate of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Pulmonx will post -1.55 EPS for the current year.

Insider Activity at Pulmonx

In other Pulmonx news, Director Richard Ferrari sold 8,000 shares of the company's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $3.16, for a total transaction of $25,280.00. Following the completion of the sale, the director directly owned 87,024 shares of the company's stock, valued at approximately $274,995.84. This represents a 8.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel P. Florin acquired 23,321 shares of Pulmonx stock in a transaction on Thursday, June 5th. The shares were purchased at an average cost of $3.06 per share, with a total value of $71,362.26. Following the completion of the purchase, the director directly owned 117,231 shares of the company's stock, valued at approximately $358,726.86. This represents a 24.83% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 43,388 shares of company stock valued at $136,044. Corporate insiders own 6.80% of the company's stock.

Institutional Trading of Pulmonx

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in Pulmonx during the fourth quarter valued at about $43,000. ProShare Advisors LLC purchased a new stake in Pulmonx during the fourth quarter valued at about $72,000. Stifel Financial Corp purchased a new stake in Pulmonx during the fourth quarter valued at about $81,000. Vontobel Holding Ltd. purchased a new stake in Pulmonx during the first quarter valued at about $82,000. Finally, Corton Capital Inc. acquired a new position in shares of Pulmonx in the 2nd quarter valued at about $32,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.